Articles by
-
FDA Approves Treatment for Wider Range of Patients With Heart Failure
The FDA approved empagliflozin (Jardiance) to reduce the risk of cardiovascular death and hospitalization for heart failure in…
-
New Migraine Treatment Approved in Adults
Celecoxib oral solution (Elyxyb) was approved for the acute treatment of migraine with or without aura in adults.…
-
CDC Advises Moderately or Severely Immunocompromised Teens, Adults to Get Fourth COVID-19 Shot
The Centers for Disease Control and Prevention (CDC) advised that moderately or severely immunocompromised teens and adults receive…
-
New-Onset Bladder Symptoms in Discharged COVID Patients
Men and women who have been hospitalized with COVID-19 have reported new-onset severe genitourinary symptoms, including increased frequency,…
-
FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to Omicron Variant
The FDA revised the authorization for two monoclonal antibody treatments, bamlanivimab and etesevimab (administered together) and REGEN-COV (casirivimab…
-
FDA Approves Remdesivir (Veklury) for Outpatient COVID-19 Treatment
The FDA has expanded the approved use of remdesivir (Veklury) to certain non-hospitalized adults and pediatric patients for…
-
FDA Formally Approves Moderna’s COVID-19 Vaccine
The FDA formally approved the second COVID-19 vaccine, Moderna’s COVID-19 vaccine, which will be marketed as Spikevax. Spikevax…
-
First Generic of Cyclosporine Ophthalmic Emulsion Eye Drops (Restasis) Approved for Dry Eye
The FDA approved the first generic version of cyclosporine ophthalmic emulsion 0.05% single-use vials (Restasis) to increase tear…
-
CDC Issues Simplified New Recommendations for Pneumococcal Vaccination in Adults
Updated pneumococcal vaccine recommendations for adults were issued by the Centers for Disease Control and Prevention, calling for…
-
Rivaroxaban (Xarelto) Approved for Pediatric Indication to Help Prevent, Treat Clots
The FDA approved two new pediatric indications for rivaroxaban (Xarelto), a factor Xa anticoagulant with multiple indications in…
-
New Medication Spray Approved for Seasonal Allergic Rhinitis
The FDA approved olopatadine hydrochloride/mometasone furoate (Ryaltris) nasal spray, a combination histamine-1(H1)-receptor inhibitor/corticosteroid, for the treatment of symptoms…
-
National NP Practitioner Residency & Fellowship Training Consortium Receives Federal Recognition as Accrediting Agency
The National Nurse Practitioner Residency & Fellowship Training Consortium received federal recognition as accrediting agency by the US…
Join our email list
Get new course alerts, newsletters and more delivered directly to your inbox
By providing my personal information, including phone number, I consent to (1) receive email messages with information and offers, autodialed calls, texts, and prerecorded messages from FHEA, including current and possible future services, customer service and billing; and (2) FHEA’s Privacy Policy and Terms and Conditions. I understand that my consent is not required to purchase, and that cancellation of purchase does not automatically revoke this consent.